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Leukaemogenic mutations commonly disrupt cellular differentiation and/or enhance pro-
liferation, thus perturbing the regulatory programs that control self-renewal and differ-
entiation of stem and progenitor cells. Translocations involving the Mll1 (Kmt2a) gene
generate powerful oncogenic fusion proteins, predominantly affecting infant and paediatric
AML and ALL patients. The early stages of leukaemogenic transformation are typically
inaccessible from human patients and conventional mouse models. Here, we take advantage
of cells conditionally blocked at the multipotent haematopoietic progenitor stage to develop a
MLL-r model capturing early cellular and molecular consequences of MLL-ENL expression
based on a clear clonal relationship between parental and leukaemic cells. Through a com-
bination of scRNA-seq, ATAC-seq and genome-scale CRISPR-Cas9 screening, we identify
pathways and genes likely to drive the early phases of leukaemogenesis. Finally, we
demonstrate the broad utility of using matched parental and transformed cells for small
molecule inhibitor studies by validating both previously known and other potential ther-
apeutic targets.
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Chromosomal rearrangements involving the Mixed LineageLeukaemia gene (MLL-r) cause more than 70% of infantleukaemias with either myeloid (AML) or lymphoid (ALL)
immunophenotype1,2. MLL-r also occur in 10% of adult AML
cases, and in therapy-related acute leukaemias (t-ALs)3,4. Several
retroviral and non-retroviral mouse models bearing MLL fusion
proteins have advanced our understanding of MLL-fusion-
mediated leukaemogenesis. The first retroviral MLL-fusion leu-
kaemia model5 employed retroviral transduction into lineage
depleted or c-Kit sorted mouse bone marrow haematopoietic
stem/progenitor cells (HSPCs) followed by culture in methylcel-
lulose and subsequent injection into immunodeficient mice. A
key goal of non-retroviral mouse models has been to achieve
fusion gene expression levels representative of the endogenous
gene loci involved in the translocation events6,7. However, there
has been substantial phenotypic variation between the various
mouse models.
One of the main causes of inconsistencies comes from the
differences in the target cells, where different fluorescence-
activated cell sorting (FACS) strategies result in overlapping but
not identical populations. The use of two different sorting stra-
tegies for HSCs for example resulted in reports that MLL-r can8 or
cannot9 transform the target cells. When assayed at the single-cell
level either functionally or by molecular profiling, all con-
ventionally defined haematopoietic stem/progenitor populations
display substantial heterogeneity10–12. Consequently, the exact
nature of the parental cell that has been transformed in any of the
traditional retroviral leukaemia models remains ill defined. Studies
aiming to decipher the early stages of leukaemic transformation
are therefore impeded, and there is no appropriate cell type that
can be used as wild-type control to represent the starting cells
when testing putative drug candidates. Importantly, the com-
monly used Lineage negative (Lin−, mouse) or CD34 positive
(CD34+, human) control cells do not address these issues, because
these populations are very heterogeneous, and include stem cells
but also erythroid, myeloid and lymphoid progenitors12,13.
Cell lines that are conditionally blocked at the stage of stem/
progenitor and maintain intact differentiation potential represent
an attractive approach for deriving defined and reproducible
sources of HSPCs. Cell line models requiring cytokines for their
in vitro growth have been particularly sought after, as cytokine
dependence represents a key aspect of the normal physiology of
primary HSPCs14,15. The LMPP-like Hoxb8-FL cell line16 stands
out because of its validated multilineage in vitro and in vivo
differentiation capacity. Hoxb8-FL cells carry a glucocorticoid-
controlled Hoxb8 transgene, and require Hoxb8 induction as well
as externally supplied Flt3 ligand (Flt3L) for in vitro propagation
(self-renewal condition). Withdrawal of Hoxb8 coupled with
various cytokine combinations allows directed differentiation into
both myeloid and lymphoid lineages from a clonally derived
precursor cell.
Here we report the development and validation of a mouse
model of MLL-ENL-driven AML starting from Hoxb8-FL cells,
which recapitulate all key features of bone marrow-derived ret-
roviral AML models both in vitro and in vivo. Unlike previous
models, the exact nature of the target cell is known and accessible
in our model, allowing for direct comparisons between different
stages. We then use this model to identify transcriptional
changes during early leukaemogenic transformation using both
single-cell RNA-seq (scRNA-seq) and ATAC-seq approaches,
followed by genome-wide CRISPR-Cas9 screens to identify
genetic vulnerabilities specifically associated with the trans-
formed, but not the parental cells. Integrated data analysis fol-
lowed by small molecule-based functional validation identifies
therapeutic targets including DNA damage response (DDR) and
metabolic pathways.
Results
Development of a clonal mouse model of MLL-ENL-driven
AML. Highly purified HSPC populations are recognised to be
heterogeneous10,17. Therefore, it is difficult to define a precise
wild-type parental control in conventional retroviral transduction
leukaemia models. To circumvent this problem, we devised a
strategy based on the clonal mouse haematopoietic progenitor cell
line Hoxb8-FL16. Cells were transduced with either MSCV-MLL-
ENL-GFP (henceforth referred as ME-Parental cells) or control
MSCV-GFP (henceforth referred as Parental cells) and were
serially re-plated in methylcellulose (CFU) in the absence of Flt3L
and β-estradiol but in the presence of interleukin-3 (IL-3),
interleukin-6 (IL-6), stem cell factor (SCF) and erythropoietin
(EPO). This step was followed by liquid culture, first in the
presence of IL-3, IL-6 and SCF, then IL-3 and IL-6 and finally IL-
3 alone. Leukaemic transforming potential in vivo was assessed by
transplantation into lethally irradiated mice (Fig. 1a).
Only ME-Parental cells (transduced with the MLL-ENL virus)
were able to generate serially re-plating colonies (Fig. 1b) with a
morphology that was either compact or compact with a halo of
differentiating cells (Fig. 1c), as previously described for
conventional bone marrow progenitor transduction experi-
ments5. Following three rounds of plating in methylcellulose,
MLL-ENL-transduced cells were grown in liquid culture to
generate IL-3-dependent cells (hereafter referred to as ME-
Transformed) that were maintained for over a month, with
continuous exponential growth and a doubling time of 24 h
(Fig. 1d). When compared with the wild-type Hoxb8-FL cells,
flow cytometric analysis of the ME-Transformed sample showed
acquisition of the myeloid surface markers CD11b and Gr-1 and
downregulation of c-Kit (Fig. 1e). Of note, ME-Transformed cells
did not show expression of CD11c, MHC class II, B220 and F4/
80, reminiscent of an immature myeloid differentiation stage
(Supplementary Fig. 1a, b).
To validate the generated MLL-ENL model in vivo, we
transplanted Parental cells (n= 5) or ME-Transformed cells
(n= 5) into lethally irradiated mice, together with CD45.2 bone
marrow donor-derived cells. Development of acute myeloid
leukaemia (AML) was monitored via flow cytometry of the
peripheral blood. All mice transplanted with the MLL-ENL-
transduced cells developed AML within 75 days; while none of
the parental mice developed disease up to 100 days after injection
(Fig. 1f), confirmed by the absence of GFP+ cells in the peripheral
blood, spleen and bone marrow (Supplementary Fig. 1c).
Characteristic features of AML including splenomegaly and
hepatomegaly were only observed in mice transplanted with ME-
Transformed cells (Fig. 1g and Supplementary Fig. 1d), consistent
with previous reports of bone marrow haematopoietic progenitor
cells transduced with MLL-ENL as well as other MLL fusion
genes5,18.
To further understand the clonal relationship within our
model, we characterised GFP+ cells obtained from three different
animals at the time of culling using flow cytometry (Supplemen-
tary Fig. 1e) and performed exome sequencing of these cells
together with Parental and ME-Transformed cells. No additional
driver mutations were found in cells obtained from leukaemic
animals (Supplementary Data 1). The in vitro and in vivo
experiments therefore validate our MLL-ENL-transduced cells as
a preleukaemic model for AML, facilitating access to the early
stages of transformation and providing authentic parental control
cells for molecular and cellular comparisons.
Leukaemogenic program requires exiting self-renewal condi-
tions. To investigate the transcriptional consequences of MLL-
ENL expression, we sorted single GFP+ Parental, ME-Parental
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and ME-Transformed cells into 96-well plates for single-cell
gene expression analysis (Fig. 2a). Conventional bone marrow
progenitors transduced with MLL-ENL (hereafter referred to as
MLL-ENL BM)19 were included as positive controls. Single
Parental and ME-Parental cells were processed for scRNA-seq
using the Smart-Seq2 protocol20. ME-Transformed and MLL-
ENL BM cells cultured in the presence of IL-3 were similarly
profiled.
Principal component analysis (PCA) separated in the first
component cells dependent on Flt3L and β-estradiol from IL-3-
dependent transformed cells (Fig. 2b and Supplementary Fig. 2a).
Analysis of the genes underlying this separation (PC1 loadings)
revealed that Parental and ME-Parental cells expressed genes
such as Ddx4, Cd34 and Ebf1 confirming the mixed lineage
potential of Hoxb8-FL cells as described by Redecke et al.16. By
contrast, both the MLL-ENL BM and ME-Transformed samples,
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adapted to growth in IL-3, expressed myeloid lineage genes such
as the neutrophil lineage marker Elane21 and the granulocyte
marker Ly6c2 (Gr-1)22 (Fig. 2c). Moreover, both samples
expressed genes previously associated specifically with MLL-
mediated leukaemic transformation such as the transcription
factor Six118,23.
To identify the likely counterparts in normal haematopoiesis
for the four populations profiled here, we projected the single-cell
transcriptomes onto a force-directed graph representation of over
40,000 published single transcriptomes from normal bone
marrow HSPCs24 (Fig. 2d). Serving as an important positive
control in this analysis, the Parental and ME-Parental cells
cultured in Flt3L and β-estradiol mapped to the region that
contained lymphoid and myeloid progenitors, consistent with
their multipotent progenitor identity. In contrast, many of the
MLL-ENL BM and ME-Transformed cells cultured in IL-3
mapped to more mature cells, clustering within the neutrophil
and more mature monocytic branches of the single-cell
transcriptional landscape.
The most surprising observation was the similarity of the
Parental with the ME-Parental cells (as evidenced by PCA
analysis and projections onto the HSPC landscape), suggesting
that overexpression of MLL-ENL alone in the Hoxb8-FL cells is
not sufficient to initiate a leukaemogenic transcriptional program.
All four cell types studied here express key genes reported to be
involved in MLL fusion-driven transformation (Meis1 and
Hoxa9)25 and genes involved in proliferation and myeloid cell
differentiation (Myb and Myc)26,27 (Fig. 2e). To investigate
further any potential impact of MLL-ENL expression on the
Hoxb8-FL cells cultured in Flt3L and β-estradiol, we compared
the transcriptional profile of ME-Parental cells to Parental cells.
We found that both cell types are very homogenous and could
not detect significant differences at the transcriptomic level
between them (Supplementary Fig. 2b). We also examined the
chromatin structure of ME-Parental cells in comparison to the
Parental cells using ATAC-seq28 given that MLL is recognised as
an “epigenetic regulator” that can influence chromatin state.
Three pools of 50,000 GFP+ cells were analysed at 6 and 9 days
post transduction. Visual inspection of key MLL leukaemia-
associated gene loci showed no significant differences in
chromatin accessibility profiles at either time point (Supplemen-
tary Fig. 2c). Moreover, following peak calling, comparison of the
coverage at all regions called as a peak in either Parental or ME-
Parental samples showed no statistical differences at either day 6
or day 9 post infection (Fig. 2f, g) and displayed a similar
genome-wide distribution (Supplementary Fig. 2d). Taken
together, our results show that MLL-ENL can induce a leukaemic
transcriptional program in Hoxb8-FL cells, but only if the cells
are taken out of their Flt3L and β-estradiol self-renewal culture
condition, reminiscent of previous studies showing that MLL-
ENL did not induce AML in mice when transduced into highly
purified HSCs9 and MLL-AF9 did not cause AML in either HSCs
or CMPs when myeloid differentiation was compromised by C/
EBPα deletion29.
Defects in cytokine-induced differentiation caused by MLL-
ENL. Previous studies indicated that AML development in the
murine MLL-AF9 model required myeloid differentiation29. To
capture early impacts of MLL-ENL on myeloid differentiation, we
took Parental and ME-Parental cells out of the Flt3L and β-
estradiol self-renewal conditions, and exposed them to one of
three myeloid differentiation cytokines: IL-3, GM-CSF or Flt3L
(Fig. 3a). Myeloid differentiation was assessed before cytokine
addition (day 0) and after 4 and 7 days of stimulation (Fig. 3b and
Supplementary Fig. 3a). Of note, all three cytokines resulted in
downregulation of c-Kit expression consistent with loss of the
immature LMPP-like phenotype of Hoxb8-FL (Fig. 3b).
Effects of MLL-ENL expression on myeloid maturation were
already evident at day 4 for the IL-3 or GM-CSF treatments,
and then also for Flt3L at day 7. An overall delay of myeloid
differentiation was apparent, since ME-Parental cells were
CD11b−/low in IL-3 or GM-CSF at day 4 and in Flt3L at day 7,
whilst the majority of the Parental cells were CD11bhigh at the
same time points. By day 7, the difference in myeloid maturation
of ME-Parental cells compared to Parental was particularly large
for both the IL-3 and GM-CSF treatments (Supplementary
Fig. 3b). Following IL-3 exposure, 62.8% of MLL-ENL cells
displayed a granulocyte phenotype being CD11blow Gr-1+, with
reduced levels of antigen-presenting cell markers (CD11c, MHC
II and B220) and the macrophage marker F4/80 (Supplementary
Fig. 3a). Parental cells, on the other hand, generated a mixture
of more mature cells, such as macrophages (CD11b+ Gr-1−
MHCII+ CD11c+ B220+ F4/80+) and dendritic cells (CD11b+
Gr-1− MHCII+ CD11c+ B220− F4/80+/−) (Fig. 3b and Supple-
mentary Fig. 3a). A similar cell progeny was generated in the
presence of GM-CSF. However, the MLL-ENL-derived granulocyte
population obtained in the presence of GM-CSF was much smaller
than in the presence of IL-3, accounting for only 26% of the
total cells (Fig. 3b and Supplementary Fig. 3b). Finally, Flt3L
stimulation, previously reported to drive dendritic cell (DC)
maturation16,30,31, showed a consistent reduction of Cd11b and
Gr-1 expression when compared to Parental-derived cells (Fig. 3b
and Supplementary Fig. 3b).
Fig. 1 Development of a clonally derived MLL-ENL mouse model. a Schematic outline of in vitro and in vivo experimental scheme. Hoxb8-FL cells were
transduced with MLL-ENL or empty virus to generate ME-Parental and Parental cells, respectively. When cultured in methylcellulose without Flt3L and
estradiol (causing retention of Hoxb8-ER in the cytoplasm), only ME-Parental cells had re-plating capabilities. These cells were transferred to liquid culture
supplemented with IL-3, IL-6 and SCF. Sequentially, SCF and IL-6 were removed to obtain ME-Transformed cells able to grow long term in the presence of
IL-3. These cells were then tail injected into lethally irradiated mice, followed by close monitoring of engraftment and disease onset. b Bar graph showing
colony numbers at each round of methylcellulose plating (every 7 days). Mean and SEM are represented. N= 3 biologically independent experiments.
c Colonies generated in methylcellulose by MLL-ENL-transduced Hoxb8-FL cells are characterised by either a compact centre or a compact centre with a
halo of differentiating cells (images taken using an EVOS® inverted fluorescence microscope). This experiment was repeated three times with similar
results. d Growth curve of ME-Transformed cells following dissociation of methylcellulose colonies obtained after three replatings. Cells were kept in liquid
culture supplemented with IL-3, IL-6 and SCF for two passages. SCF was removed from the culture for the following two passages, IL-6 was then also
removed after two passages and then cells were cultured only with IL-3. e Phenotypic characterisation of untransduced (Hoxb8-FL) and transduced
(Parental and ME-Parental) cells cultured in the presence of Flt3L and β-estradiol compared to ME-Transformed cells cultured in IL-3-only medium. ME-
Transformed cells showed upregulation of myeloid markers CD11b and Gr-1 and downregulation of c-Kit, in contrast to Hoxb8-FL, Parental and ME-Parental
cells. f Survival curve of mice transplanted with either Parental cells (n= 5) or ME-Transformed cells (n= 5) (two-sided log-rank Mantel-Cox test.
****p value= 0.0031). g Graphs showing difference in spleen (**p= 0.0028) and liver (**p= 0.0052) weight between ME-Transformed and Parental
mice. Average of five mice per condition ± SEM, two-tailed unpaired t test. Source data are provided as a Source Data file.
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We also assessed cell proliferation during a 7-day time course
of myeloid differentiation. For IL-3 and Flt3L differentiation
conditions, ME-Parental cells displayed a statistically significant
increase in cell numbers compared to the Parental samples
(Fig. 3c). This observation is consistent with the phenotypic
analysis above given the known reduction in proliferation in
mature myeloid cells. Cell cycle promotion by MLL-ENL was also
confirmed by flow cytometry, which revealed a trend in the
decrease in G1 and an increase in S and G2 phase, evident in the
IL-3 and Flt3L treatments (Fig. 3d and Supplementary Fig. 3c).
Taken together, induction of myeloid differentiation reveals early
cellular consequences of MLL-ENL expression culminating in
reduced terminal myeloid differentiation and increased cell
proliferation.
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Early molecular changes during MLL-ENL transformation.
Having defined early cellular consequences of MLL-ENL
expression following the induction of myeloid differentiation,
we next explored the corresponding molecular changes. Given the
strong phenotype observed after 7 days of differentiation, we
performed scRNA-Seq on Parental and ME-Parental cells fol-
lowing 7 days of differentiation in IL-3, GM-CSF and Flt3L
together with ME-Transformed and MLL-ENL BM cells (Sup-
plementary Fig. 4a, b). IL-3 was the most effective cytokine to
produce cells similar to ME-Transformed and MLL-ENL BM
cells. We therefore concentrated our analysis on IL-3-
differentiated ME-Parental and Parental cells (Fig. 4a). Cells
were first stained with myeloid differentiation surface markers
(Fig. 3b and Supplementary Fig. 3b), then GFP+ME-Parental
and Parental single cells were sorted and processed using the
Smart-seq2 protocol. PCA of the single-cell transcriptomes
revealed two MLL-ENL sub-populations (hereafter referred to as
MLL-ENL 1 and 2) (Fig. 4b and Supplementary Fig. 4c). Of note,
there was a trend towards higher expression of the transgene in
MLL-ENL1 cells compared to MLL-ENL2 cells, although it did
not reach statistical significance (p value > 0.05), as shown in
Fig. 4c. These two populations most likely reflect heterogeneity in
the response to the initial change of conditions, as opposed to the
more homogenous nature of ME-Transformed cells, which have
been cultured in IL-3 long-term (Fig. 2b).
Retrospective analysis of index sort data (Fig. 4d and
Supplementary Fig. 4d) showed that the majority of MLL-ENL2
and Parental cells resembled conventional DCs (MHCII+ CD11c+
B220−F4/80+ CD11b+ Gr-1+)16 and a few resembled macro-
phages (MHCII+ CD11c+ B220+ F4/80+ CD11b+ Gr-1+)32,33,
while the MLL-ENL1 sub-population was made up of cells
displaying a granulocytic phenotype (CD11blow and Gr-1+).
Differential expression analysis confirmed the phenotypic char-
acterisation identified via flow cytometry, since the MLL-ENL1
population showed elevated expression of the neutrophil-related
genes Mpo and Prtn334–36 with low expression of MHC class II
genes such as H2-Ab1 and H2-Eb1, known to be expressed on the
surface of DCs and macrophages37,38 (Fig. 4e).
To define the early molecular changes associated with MLL-
ENL expression, pairwise differential expression analysis was
performed among MLL-ENL1, MLL-ENL2 and Parental samples
(Supplementary Data 2). Genes included for further analysis were
selected according to the following parameters: FDR < 0.1 and
base mean expression value for each gene larger than 30.
Unsupervised hierarchical clustering identified three different
gene clusters (Fig. 4f). Genes in cluster 1 (C1), which included
mitotic cell cycle genes, were higher expressed in the MLL-ENL1
population. MLL-ENL2 and Parental populations expressed
higher levels of genes contained in clusters 2 (C2) and 3 (C3),
which included immune response-related genes. Additional GO
categories were identified using the FastProject tool39 for
exploration of gene signatures using two-dimensional projections
such as PCA. Figure 4g shows that MLL-ENL1 was particularly
enriched for gene sets such as “Formation of translation
preinitiation complex”, “DNA replication initiation” and “glycine
metabolic process”25,40,41 which may be associated with the
increase in cell cycle gene expression previously shown; and
“positive regulation of telomerase activity”, previously reported as
a promising target for AML cell eradication42.
Following on from bioinformatic analysis of day 7 cells only,
we next explored to what extent these early transcriptomic
changes might foreshadow the transcriptional events character-
istic of fully transformed MLL-ENL cells adapted to grow long-
term in IL-3. We therefore repeated the PCA from Fig. 4b
(corresponding to Parental and ME-Parental cells differentiated
in IL-3 for 7 days), including the single-cell transcriptomes of
MLL-ENL BM and ME-Transformed cells (corresponding to fully
transformed MLL-ENL cells). As shown in Fig. 4h, only MLL-
ENL1 clustered together with MLL-ENL BM and ME-
Transformed cells, all expressing the neutrophil marker gene
Elane (Fig. 4i). By contrast, MLL-ENL2 and Parental cells
clustered separately from all the other samples, and expressed
high levels of Cd74, an antigen-presenting cell marker. Known
target genes of MLL fusion proteins were elevated in MLL-ENL1
as well as the MLL-ENL BM and ME-Transformed cells, while
regulators of myeloid differentiation showed reduced expression
(Fig. 4j). To understand the dynamic appearance of the MLL-
ENL1 population, we repeated the transcriptomic analysis at days
4, 7 and 11 of differentiation in the presence of IL-3
(Supplementary Fig. 4e). MLL-ENL1 cells can already be
distinguished at day 4, but they become more distinct by day 7
and increase in number by day 11.
Integration with a CRISPR screen identifies candidate targets.
Having identified that early molecular changes foreshadow the
MLL-ENL preleukaemic transcriptional program, we next
explored whether any of these early events represent genetic
vulnerabilities associated with MLL-ENL expression by per-
forming a genome-wide CRISPR-Cas9 drop-out screen in both
the Parental (Flt3L and β-estradiol dependent) as well as the ME-
Transformed cells cultured in IL-3 (Fig. 5a). Cells were trans-
duced with a genome-wide guide RNA (gRNA) lentiviral super-
natant containing 90,230 guides targeting a total of 18,424 mouse
genes (average of 3–5 guides per gene)43. Cell aliquots were
harvested at days 6, 10 and 12 post transduction and gRNA
representation determined by next-generation sequencing.
The genome-wide screen, performed using at least two
biological replicates per cell line, was analysed using MaGECK44
and this revealed 465, 1624 and 1798 depleted genes (FDR < 0.25)
Fig. 2 MLL-ENL fusion gene lacks leukaemic transforming ability in Flt3L and β-estradiol culture condition. a Outline of experimental strategy. Single
cells -Parental and ME-Parental cells cultured in the presence of Flt3L and β-estradiol, ME-Transformed and MLL-ENL BM cells cultured long term in the
presence of IL-3- were sorted into 96-well plates and processed for scRNA-seq using Smart-Seq2 protocol. b PCA plot based on highly variable genes of
166 cells. Parental (47 cells) and ME-Parental (55 cells) cells are Hoxb8/Flt3L dependent while MLL-ENL BM (32 cells) and ME-Transformed (32 cells) are
cultured long term in the presence of IL-3. c Expression of selected genes in cells in (b). Selected genes are important in defining PC1 component. Top
genes are MPP4/LMPP-specific genes; bottom genes represent myeloid and leukaemogenic genes. Cells are coloured according to the expression levels of
denoted genes. Colour scheme is based on log10 scale of normalised counts from 0 (grey) to 4 (red). d Projection of transcriptomic profiles of Parental,
ME-Parental, ME-Transformed and MLL-ENL BM cells onto force-directed graph obtained from single HSPCs. First panel shows the cell type landscape and
clustering generated by Dahlin et al.24. Following panels show the most similar cells of the landscape to Parental, ME-Parental, ME-Transformed and MLL-
ENL BM cells. e Violin plots showing expression levels (log10 scale of Normalised counts on y-axis) of key leukaemic target genes across Parental, ME-
Parental, MLL-ENL BM and ME-Transformed cells. f, gMA plots showing the comparison between counts obtained at Parental and ME-Parental accessible
regions defined via ATAC-seq at day 6 (f) or day 9 (g) of culture in the presence of β-estradiol and Flt3L. No statistical differences can be detected except
for regions corresponding to the transduced MLL-ENL (depicted in red).
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for d6, d10 and d12 ME-Transformed cells respectively, in line
with the number of drop-outs obtained using an equivalent
gRNA library on multiple AML cell lines43. As for the Parental
cell line, 1123 and 1440 depleted genes were identified for d6 and
d10 time points respectively (Supplementary Data 3). Parental
cells were also collected at day 12 but not further analysed due to
an apparent loss of guide complexity. Notably, Flt3 and Il3ra, key
essential genes for the survival of the Parental (dependent on
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Flt3L) and ME-Transformed (dependent on IL-3) cells, were
significantly depleted in the respective screens (p values of 2.69E
−07 and 8.07E−07 at d6 and d10 respectively for Flt3 in the
Parental cells and 0.1175, 6.32E−05 and 9.55E−05 at d6, d10 and
d12 respectively for Il3ra in the ME-Transformed cells). Overall,
these data confirmed the efficiency of the screen and the
biological relevance of drop-out genes.
To identify genetic vulnerabilities specific to the ME-
Transformed cells, we merged, for each cell line, drop-out genes
from all time points and intersected the resulting gene lists from
both cell lines (Fig. 5b, c and Supplementary Data 4). As expected,
the 1171 genes that dropped out in both the Parental and ME-
Transformed cells showed enrichment for essential biological
processes such as “Metabolism of RNA” and “CDK regulation of
DNA replication”, and 548 specific genes for the Parental cell line
showed enrichment for “Metabolism of RNA” and “BRCA1-PCC
network”45,46. The 897 genes that dropped out specifically in the
ME-Transformed cells on the other hand showed enrichment for
gene ontology classifications that included “mitotic cell cycle”,
“chromatin organisation”, “ATM pathway” and “Chronic mye-
loid leukaemia”47,48.
To focus on MLL-ENL-specific drop-out genes that are
associated with early transcriptional changes, we next compared
the 897 MLL-ENL-specific drop-outs with the 1553 differentially
upregulated genes between the MLL-ENL1 population (defined
following differentiation in IL-3) and the Parental cell line. The
overlap of 127 shared genes (Fig. 5d and Supplementary Data 5)
included genes with potential clinical relevance such as DHODH
(currently involved in AML and MDS clinical trials) and PRMT1
(described to play roles in haematological as well as solid cancers
and also involved in clinical trials). Overrepresented gene set
enrichment analysis (GSEA) categories included “mitotic cell
cycle” and “Activation of ATR in response to replication stress”
(Fig. 5e). The DDR pathway represents an attractive therapeutic
concept in cancer therapy especially in the context of radio- and
chemotherapy combinations, as well as synthetic lethal
approaches47. Moreover, there is pre-clinical evidence that
inhibition of DDR mediators, such as ATM and ATR, may
represent potential therapeutic strategies for AML49,50. Of note,
none of these 127 genes were upregulated in Parental cells after
7 days of culture in the presence of IL-3. We therefore
interrogated the “druggability” of the 127 overlapping genes
using the Drug Gene Interaction Database (DGIdb)51, which
reported 47 (37%) genes to be in druggable categories (Fig. 5f and
Supplementary Data 5). Taken together therefore, the genome-
wide CRISR-Cas9 screen allowed us to identify a number of
genetic vulnerabilities that are associated with early transcrip-
tional changes following transformation and are specific to the
ME-Transformed cells.
Validation of Atm, Cdc7 and Ldha as candidate drug targets.
From the 47 druggable genes, inhibitors were readily available for
three genes, allowing us to perform initial validation experiments
confirming them as potential therapeutic targets in AML (Fig. 5f).
Following confirmation of the genome-wide CRISPR-Cas9 screen
by individual gRNA targeting (Supplementary Fig. 5a), we first
tested inhibition of the Serine/Threonine Kinase gene (Atm),
which had been shown before to prolong survival of mice injected
with MLL-ENL cells49. Inhibition of the Cell Division Cycle 7
gene (Cdc7) was another promising target due to its involvement
in DNA repair52 and studies suggesting its importance in both
solid53 and liquid cancers54. Lactate Dehydrogenase A gene
(Ldha) had not been explored in AML but overexpression has
been implicated in a range of solid cancers55,56. Interestingly, we
were able to show that high Ldha expression also correlated with
poor patient survival in the Leukaemia Gene Atlas (LGA) plat-
form (Supplementary Fig. 5b).
To assess the consequences of small molecule-based target gene
inhibition, we used colorimetric assays (MTS assay) to determine
the IC50. Effects on the ME-Transformed cells were compared to
Parental and ME-Parental cells cultured in self-renewal condi-
tions, to take advantage of our sequential stages of transformation
and thus assess potential selectivity in targeting the transformed
state. As expected from previous reports49,57, the ATM inhibitor
(ATMi) (AZD0156) consistently caused a marked growth
inhibition when measured at both 48 and 72 h (Fig. 6a and
Supplementary Fig. 6a). Importantly, the IC50 of 22.9 nM for the
ME-Transformed sample at 48 h was sixfold lower compared
with the Parental and ME-Parental samples (146.6 and 135 nM
respectively). Additionally, this difference increased further after
72 h (14.2-fold decrease of ME-Transformed IC50 value com-
pared to the negative controls), and was highly significant (p
value < 0.001 at 48 h and <0.0001 at 72 h).
To test potential effects of the CDC7i (PHA-767491), we
exposed cells to higher concentrations (2000, 4000, 5000, 6000,
7000 and 8000 nM) since we did not observe effects up to 1000
nM. As shown in Fig. 6b, ME-Transformed had lower metabolic
activity and therefore lower IC50, compared to the negative
controls (Supplementary Fig. 6b). This difference became more
evident after 72 h of treatment: while ME-Transformed IC50
decreased over time, Parental and ME-Parental showed an
opposite trend with an increase of IC50s from 48 to 72 h (p <
0.001 at 48 and 72 h). To conclude, CDC7i had less impact on cell
metabolic activity compared to ATMi but showed inhibitory
effects with selectivity for the ME-Transformed cells, thus
validating the results of the CRISPR-Cas9 screen.
The third target gene Ldha selected for validation codes for a
metabolic enzyme that is able to convert pyruvate into lactate.
Much higher doses of the LDHAi (GSK 2837808A) compound
had to be used to observe an effect compared to previously
described ATMi and CDC7i treatments, possibly related to the
high Ldha expression levels compared with Atm and Cdc7
(Fig. 5f). Nevertheless, the MTS assay confirmed selectivity,
because LDHAi caused a reduction in the metabolic activity of
Fig. 3 The MLL-ENL fusion gene delays CD11b expression. a Schematic diagram representing the outline of in vitro myeloid differentiation using IL-3, GM-
CSF and Flt3L. ME-Parental and Parental cells were obtained by transduction of Hoxb8-FL cells with either MLL-ENL or empty vector control, respectively.
After removal of Flt3L and β-estradiol, Parental and ME-Parental cells were differentiated in the presence of either IL-3, GM-CSF or Flt3L. Cultures were
then analysed by flow cytometry after 4 and 7 days of differentiation taking the initial culture (day 0) as reference. b Phenotypic analysis by flow cytometry
of Parental and ME-Parental samples after culturing in presence of either IL-3, GM-CSF or Flt3L. Data were acquired after 4 and 7 days of differentiation.
Day 0 represents cells before treatment (in Flt3L and β-estradiol culture condition). Representative plots of three (N= 3) biologically independent
experiments are shown together with mean values for each gate. c Bar charts representing cell counts following 4 and 7 days of differentiation in either IL-
3, GM-CSF or Flt3L for Parental and ME-Parental cells. Values are expressed as mean ± SEM. N= 4 biologically independent experiments. Statistics were
determined by two-tailed paired t test. P values for each comparison (from left to right): 0.01, 0.001, 0.0983, 0.1627, 0.0296 and 0.0075, denoted as *p <
0.05; **p≤ 0.01. d Cell cycle analysis by flow cytometry of Parental and ME-Parental cells after 7 days of myeloid differentiation. Values are expressed as
mean ± SEM. N= 4 biologically independent experiments. Statistics were determined by two-tailed paired t test. Only statistically significant differences
are labelled; p values are 0.0080 and 0.0033 for Flt3L G1 and Flt3L S, respectively, both denoted as **. Source data are provided as a Source Data file.
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ME-Transformed cells compared to Parental and ME-Parental
cells 72 h post treatment, with IC50 values of 83.9, 118.5 and
114.5 µM respectively (ME-Transformed vs. Parental p value <
0.001 and ME-Transformed vs. ME-Parental p value < 0.01)
(Fig. 6c and Supplementary Fig. 6c). Overall, these results suggest
that our drop-out screen with matched parental and transformed
cells has indeed identified drug targets with a potential
therapeutic window.
Finally, another compound targeting the DNA repair gene Atr
was tested. The ATR pathway was a significantly enriched
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biological process for the 127 genes depleted in the drop-out
screen and upregulated at early phases of leukaemogenesis
(Fig. 5e). However, the Atr gene itself was not significantly
depleted in the drop-out screen. Treatment of cells with ATRi
(AZD6738) agreed with the results of the screening, showing no
specific effect for the MLL-transformed cells. Figure 6d and
Supplementary Fig. 6d show the IC50 values obtained after the
exposure to ATRi for 48 and 72 h, with no significant difference
(p value > 0.05) between ME-Transformed and control samples at
any of the concentrations tested. ATRi treatment therefore
further validated our drop-out screen. Overall, the small molecule
inhibitor analysis demonstrated that our integrated analysis of the
CRISPR-Cas9 drop-out screens and scRNA-seq analysis provides
a useful platform to identify potential therapeutic targets.
Discussion
MLL translocation fusion proteins represent some of the most
commonly used oncogenes for the generation of leukaemia
models generated to date. Nevertheless, key questions about the
leukaemogenic mechanisms remain unanswered, and contra-
dictions between individual studies highlight the complex inter-
play of multiple parameters such as type of MLL-r,
microenvironment, oncogene delivery method and cellular con-
text. We took advantage of cells conditionally blocked at the
multipotent haematopoietic progenitor stage to develop an MLL-r
model with a clear clonal relationship between the parental and
MLL-leukaemic cells. Through a combination of scRNA-seq
coupled with genome-scale CRISPR-Cas9 screening and inhibitor
assays, we highlight genes and pathways likely to be crucial
during early leukaemogenic evolution of the disease.
How MLL leukaemia can be initiated from different cell types
along the haematopoietic hierarchy is still under debate. MLL-
driven leukaemic transformation has been described in HSC,
CMP, GMP, CLP, MPP and LMPP5–7,9,18,19,58. Of note, MLL-
ENL was shown not to induce AML in mice when transduced
into highly purified HSCs9 and require myeloid differentiation for
efficient leukaemic transformation29, contradicting another study
suggesting that the HSC compartment is more susceptible to
transformation than GMPs8. However, the latter study sorted
Lin-c-Kit+Sca-1+CD34− cells, which include HSCs as well as
MPPs13. Importantly, single-cell molecular profiling studies
emphasise the notion that all classical populations purified by
flow cytometry display substantial heterogeneity17,59, which
means that the exact nature of the target cell for transformation
will remain obscure when using these conventionally defined
populations.
To overcome these limitations, we took advantage of the
conditionally blocked in differentiation and cytokine-dependent
mouse haematopoietic progenitor cell line Hoxb8-FL16 to
model MLL-ENL-induced leukaemia, which mirrors the beha-
viour of classically derived MLL-ENL cell lines both in vitro
and in vivo18,19, but in addition also shows a clear linear
relationship between the parental and transformed states. Of
note, our AML model revealed that expression of MLL-ENL
only had very limited impact on the transcriptome as well
as open chromatin status of the Hoxb8-FL cells as long as
they were cultured in multipotent, self-renewal conditions
(ME-Parental cells), reminiscent of a previous report suggesting
that highly purified HSCs are intrinsically protected against
MLL-ENL-mediated transformation9. However, MLL-ENL-
mediated transcriptional dysregulation was readily captured
in our model when ME-Parental cells were exposed to
an adequate stimulus, for instance myeloid differentiation29,
which allowed us to demonstrate that (i) gene expression
changes during early myeloid differentiation correspond
to immediate activation of the leukaemogenic program, and
(ii) some of the transduced cells differentiated normally
despite the expression of MLL-ENL, thus enhancing our
broader understanding of the cellular permissiveness for AML
development.
Our full transcriptome analysis of expression changes asso-
ciated with early transformation was perfectly suited to being
coupled with genome-scale CRISPR drop-out screens to
prioritise genes and pathways based on their selective impor-
tance for transformed cell growth. This included the DDR
(DNA Damage Response) and several metabolic pathways,
some of which had already been described in MLL-r frank
leukaemia41,49,60, but our MLL-ENL model was able to identify
their importance also at early phases of transformation. It is
important to note that the Parental cells grow faster than the
ME-Transformed cells, yet the DNA repair and cell cycle genes
identified in here were specific drop-outs in the ME-
Transformed cells. These genes were also upregulated in the
expression analysis. This can be interpreted as an indication
that ME-Transformed cells have adopted a cellular state where
cell division (proliferation) is counterbalanced by pushes to
differentiate and/or die. Upregulation of genes such as ATM
may be required to mitigate the resulting strain, consistent with
our observation that even though the ME-Transformed cells
express higher levels of these genes, they are nevertheless
more sensitive to the inhibitors. Small molecule inhibitors to
CDC7 and LDHA showed selective activity in the transformed
cells compared with their parental counterparts, although the
Fig. 4 IL-3 stimulation captures early events of MLL-ENL leukaemic transformation. a Schematic diagram of in vitro IL-3 scRNAseq. Parental and ME-
Parental cells, after Flt3L and β-estradiol removal, were cultured with IL-3 for 7 days, then single GFP+ cells were sorted and processed using Smart-Seq2.
b PCA plot based on highly variable genes of Parental (37 cells) and ME-Parental (42 cells) cells differentiated in IL-3 for 7 days. ME-Parental cells were
subdivided into MLL-ENL1 (20 cells) and MLL-ENL2 (22 cells) according to their similarity to Parental differentiated cells. c Violin plots showing
distribution and expression (log10 scale of normalised counts) of GFP and hMLL-ENL genes across IL-3 differentiated Parental (red), MLL-ENL1 (blue) and
MLL-ENL2 (green) samples. d Flow cytometry levels of CD11b, Gr-1 and MHCII for cells analysed by scRNA-Seq in panel (b) obtained by index sort. e Violin
plots showing distribution and expression of granulocyte genes (Mpo and Prtn3) and antigen-presenting cell markers (H2-Ab1 and H2-Eb1) across IL-3
differentiated samples analysed in panel (b). f Heat map showing the top GO categories defined by GSEA by Z-score transformed expression of the most
differentially expressed genes specific for each GO category: C1, “Mitotic cell cycle” (adjusted p value= 3.49E-21); C2 “Antigen processing and
presentation via MHCII” (adjusted p value= 6.65E-13); C3 “Lysosome/Positive regulation of immune system” (adjusted p values= 7.78E-06 and 2.37E-
05, respectively). g GO annotation based on the PCA plot using FastProject39 (significance score of GO terms with red as the highest and green as the
lowest). h PCA based on highly variable genes including IL-3 differentiated cells (Parental, MLL-ENL1 and MLL-ENL2) and cells cultured long term in IL-3
(ME-Transformed and MLL-ENL BM). i Expression of selected genes in cells in panel (h). Selected genes (Elane, Cd74) are important in defining PC1
component. Cells are coloured according to the expression levels of denoted genes (log10 scale of normalised counts from 0 (grey) to 5 (red)). j Violin
plots showing distribution and expression of known MLL-fusion target genes (top genes) and regulators of myeloid differentiation (bottom genes) across
all samples analysed in panel (h).
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concentrations of compound required were higher than for the
ATM protein, especially in the case of LDHA and in line with
previous reports using solid cancer cell lines61,62. Future
development of more potent inhibitors may unlock the tar-
geting of metabolic pathways as viable treatment strategies
in AML.
Methods
Materials and methods are summarised below, with more detailed experimental
protocols provided in Supplemental Information.
Retroviral production and transduction of Hoxb8-FL cell line. pMSCV-neo
retroviral vector, containing human MLL-ENL (hMLL-ENL) cDNA63, was digested
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in order to remove neo resistance. IRES-eGFP sequence was PCR amplified from
pMSCV-PIG-IRES-eGFP vector (Addgene) using KAPA HiFi HotStart ReadyMix
PCR Kit (KAPA BIOSYSTEMS) and cloned into MSCV-MLLENL. Retroviral
production and transduction of Hoxb8-FL cells was performed via spinoculation as
indicated in Supplementary Methods, also described in ref. 64. Parental and ME-
Parental GFP+ cells were FACS sorted 6 days after spinoculation using a Melody
cell sorter (BD Biosciences). Sorted cells were then cultured typically for 3 more
days before performing further experiments.
Cell culture. Parental cells (Hoxb8-FL cells) were cultured in RPMI 1640 medium
(Sigma-R8758) supplemented with 10% fetal bovine serum (FBS) (HyCloneTM GE
Healthcare), 1% penicillin/streptomycin (Sigma-P0781), 1% L-Glutamine (Sigma-
G7513), 0.1% 2-Mercaptoethanol (50 mM stock)(Gibco®), cell culture supernatant
from an Flt3L-producing B16 melanoma cell line (5% final concentration) and
1 µM β-estradiol (Sigma-E2758), as originally described16. ME-Parental cell line
was cultured as Parental cells. ME-Transformed and MLL-ENL BM were cultured
in RPMI 1640 medium (Sigma-R8758) supplemented with 10% FBS (HyCloneTM
GE Healthcare), 1% penicillin/streptomycin (Sigma-P0781), 1% L-Glutamine
(Sigma-G7513), 0.1% 2-Mercaptoethanol (50 mM stock) (Gibco®) and 10 ng/ml
of recombinant murine interleukin 3 (IL-3) (PeproTech). All cell lines were kept at
a concentration of 1–10 × 105 cells/ml and the medium was replenished every
1–2 days.
Generation of MLL-ENL (ME)-Transformed cell line. Hoxb8-FL cells were
transduced with pMSCV-MLL-ENL-IRES-eGFP retroviral vector. ME-
Transformed cell line was then generated by serial re-plating on methylcellulose5.
Briefly, GFP-positive cells were FACS sorted, washed twice and seeded on
methylcellulose as for colony-forming assays (see below). Colonies were recovered,
washed and re-plated every 7 days. At the third re-plating, colonies were recovered,
washed and transferred to liquid culture containing RPMI 1640 medium (Sigma-
R8758) supplemented with 10% FBS (HyCloneTM GE Healthcare), 1% penicillin/
streptomycin (Sigma-P0781), 1% L-Glutamine (Sigma-G7513), 0.1% 2-
Mercaptoethanol (50 mM stock) (Gibco®), 10 ng/ml of recombinant murine
interleukin 3 (IL-3) (PeproTech), 10 ng/ml of recombinant murine interleukin 6
(IL-6) (PeproTech) and 50 ng/ml of recombinant murine stem cell factor (SCF)
(PeproTech). After two passages, SCF was removed from the media and following
two more passages, IL-6 was also removed. Finally ME-Transformed cells were
cultured long term in the presence of IL-3 only.
Fig. 5 Genome-wide drop-out screens identify new therapeutic targets. a Summary of the experimental approach. Parental and ME-Transformed cells
were obtained as described in Fig. 1a from Cas9-expressing Hoxb8-FL cells. Then, Parental cells (cultured in self-renewal conditions) and ME-Transformed
cells (IL-3 dependent) were infected with a lentiviral pool bearing a genome-wide gRNA library. Forty-eight hours post transduction, puromycin was added
in order to select for efficiently infected cells. Cell aliquots were then sampled at days 6, 10 and 12 post infection. DNA was extracted, gRNAs were PCR
amplified and subsequent libraries were sequenced. Enriched or depleted gRNAs were determined by comparison to the library used for infection. Depleted
guides represent genes whose expression is required for cell survival. b Intersection of drop-outs selected with FDR < 0.25 of Parental and ME-
Transformed samples. c Table showing top significant pathways enriched in each cell subgroup identified in (b). The GSEA database was used and an
FDR < 0.05 was applied to define a pathway as statistically significant. Individual FDR values are shown. d Venn diagram showing intersection between
unique ME-Transformed drop-outs and upregulated genes obtained from comparing the transcriptomic profile of MLL-ENL1 and Parental cells (refers to
Fig. 4). e GSEA analysis of pathways using the 127 overlapping genes identified. An FDR < 0.05 was applied to define a pathway as statistically significant.
fMA plot showing expression levels of each of the 127 overlapping genes in ME-Transformed cells (expressed as log10) against its difference of expression
in the comparison MLL-ENL1 vs. Parental (expressed as log2 of the fold-change). Genes defined as druggable are highlighted in red; genes selected for
validation (Supplementary Fig. 5) and further analysis are in bold.
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Fig. 6 ATMi, CDC7i, LDHAi and ATRi treatments validate the genome-wide CRISPR screen. a–d Plots showing IC50 fitting curves and IC50 values at
72 h post treatment of Parental, ME-Parental (cultured in presence of Flt3L and β-estradiol) and ME-Transformed (cultured in the presence of IL-3) with
inhibitors against ATM (a), CDC7 (b), LDHA (c) and ATR (d). Data are shown as mean of biological replicates; N= 2 biologically independent
experiments. Source data are provided as a Source Data file.
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Haematopoietic colony-forming assay. Two hundred GFP-positive MLL-ENL or
empty vector-transduced Hoxb8-FL cells (ME-Parental and Parental cells respec-
tively) were FACS sorted in RPMI 1640 with 10% FBS and 1% P/S. Cells were then
centrifuged at 300 × g for 5 min, resuspended in 100 μl of RPMI 1640 with 10% FBS
and 1% P/S and added to 1.1 ml of M3434 Methocult (Stem Cell Technologies).
1.2 ml of methylcellulose-cell mix was plated in 35 mm dishes in triplicate. Cells
were cultured at 37 °C with 5% CO2. Colonies were counted after 7 days, dis-
sociated in 5ml of 1× PBS, centrifuged at 300 × g for 5 min, re-suspended in 1ml of
RPMI 1640 with 10% FBS and 1% P/S and counted. For subsequent re-plating
experiments, 800 cells were re-plated in 1.1ml of methylcellulose as described above.
Myeloid differentiation assay. ME-Parental and Parental cells maintained in the
presence of Flt3L and β-estradiol were washed twice in 1× PBS and 1 × 105 cells
were plated in a six-well plate in 1 ml of myeloid differentiation media. Differ-
entiation media consisted of RPMI 1640 medium (Sigma-R8758) supplemented
with 10% FBS (HyCloneTM GE Healthcare), 1% penicillin/streptomycin (Sigma-
P0781), 1% L-Glutamine (Sigma-G7513), 0.1% 2-Mercaptoethanol (50 mM stock)
(Gibco®) and either 5% Flt3L conditional media, or 7 ng/ml mGM-CSF (Pepro-
Tech) or 10 ng/ml mIL-3 (PeproTech). Cells were cultured at 37 °C and 5% CO2.
Cells were kept in differentiation media for 7 days, and both suspension and
adherent cells were counted at days 4 and 7 and diluted to 5 × 105 cells/ml if
necessary.
Flow cytometry and sorting strategies. Cells were centrifuged at 300 × g for
5 min, washed twice in 1× PBS and incubated in 50 μl Fc-block (BioLegend) at
room temperature for 5 min. Following blocking step, 50 μl of antibody mixture
diluted in FACS buffer (1× PBS plus 2%FBS) was added and samples were incu-
bated for 30 min at 4 °C. In parallel, single staining controls using UltraComp
eBeads™ Compensation Beads (Thermo Fisher) and Fluorescence Minus One
(FMO) were prepared.
Single-cell sorting for Smart-Seq2 was performed using an Influx cell sorter (BD
Biosciences, San Jose, CA). Cells were sorted into lysis buffer and processed as
described below. The LSRFortessa (BD Biosciences) was used to analyse the cells.
The flow cytometry data were analysed using FlowJo software v10.6.1 (Treestar,
Ashland, OR).
Antibodies used are listed in Supplementary Methods.
Cell cycle analysis. Cells were centrifuged at 300 × g for 5 min and stained in
500 μl of 20 μg/ml Hoechst 33342 (Biolegend) for 45 min at 37 °C. Cells were then
centrifuged at 300 × g for 5 min at 4 °C, washed in cold medium and resuspended
in 500 μl of cold medium in addition with 7-aminoactinomycin D (Thermo Fisher
Scientific) (1:125). The LSRFortessa (BD Biosciences) was used to run and analyse
the cells.
Single-cell RNA sequencing (scRNA-seq). Cells were single-cell sorted by FACS
directly into individual wells of a 96-well plate containing lysis buffer and pro-
cessed using Smart-Seq2 protocol20. Libraries were prepared from ~150 pg of DNA
using the Illumina Nextera XT DNA preparation kit. Pooled libraries were run on
the Illumina HiSeq 4000, then raw reads were aligned to Mus musculus genome
(GRCm38.81) using G-SNAP (version 2015-09-29) with the following parameters:
–B 5 –n 1 –N 1 –Q. HTSeq-count (version 0.6.0) was run to assign mapped reads
to Ensembl genes (GRCm38.81).
ATAC-seq. Three pools of 50,000 ME-Parental and Parental cells each, cultured in
the presence of Flt3L and β-estradiol, were bulk sorted into 1.5 ml tubes and
processed following the established ATAC-seq protocol28. Samples were sequenced
on the Illumina HiSeq 4000. Reads were aligned to Mus musculus genome
(GRCm38.81) using Bowtie2 (v2.2.5), obtaining 55% of unique mappable reads.
Peak calling was run using F-Seq65 (v3) with the following parameters: -t14, -f1.
Peaks called for either Parental or ME-Parental were considered for further ana-
lysis. MA plots for comparison between Parental and ME-Parental were obtained
using DESeq266 (v1.26.0).
In vivo injection of ME-Transformed cell line. For tumour induction, 5 × 105
ME-Transformed or Parental cells (CD45.1+), together with 2 × 105 CD45.2+
total bone marrow cells were injected via tail-vein injection into lethally irradiated
C57BL/6J mice. Ten mice were used in total: five mice injected with ME-
Transformed cells and five mice with Parental cells. Blood samples were taken on
days 7, 14, 21 and 31 post transplantation and chimaerism levels were assessed via
flow cytometry using GFP, CD45.1+ (Biolegend, clone A20) and CD45.2+ (Bio-
legend, clone 104) staining.
Mice. Six-week-old female C57BL/6J mice were bred and maintained at the Uni-
versity of Cambridge in microisolator cages and provided continuously with sterile
food, water, and bedding. All mice were kept in specified pathogen-free conditions,
and all procedures were performed according to the United Kingdom Home Office
regulations.
CRISPR-Cas9 screening. CRISPR-Cas9 genome-wide screening was performed
following the methodology described by Tzelepis et al.43. Briefly, Cas-9 expressing
cells were generated first by lentiviral transduction using pKLV2-EF1aBsd2ACas9-
W and blasticidin (10 µg/ml) selection applied 2 days post infection. In order to
perform CRISPR-Cas9 screening, Cas-9-expressing cells were infected with
genome-wide gRNA lentiviral supernatant. Forty-eight hours post transduction,
cells were selected with puromycin. Selected cells were harvested at days 6, 10 and
12 post infection, DNA was extracted and gRNAs libraries were generated for
Illumina sequencing (HiSeq2500).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The genome-wide CRISPR screening and exome sequencing data referenced during the
study have been deposited in the European Nucleotide Archive (http://www.ebi.ac.uk/
ena) with numbers ERP118720 and ERS529672 and ERP117027. scRNA-seq and ATAC-
Seq data have been deposited in the GEO database (https://www.ncbi.nlm.nih.gov/geo/)
under the accession numbers GSE140807 and GSE141353, respectively. Normal bone
marrow HSPC dataset published by Dahlin et al.24 was obtained from GEO database,
accession number GSE107727. The source data underlying Figs. 1b–g, 3b–d, 6a–d and
Supplementary Figs. 3a–c, 5a, 6a–d are provided as a Source Data file. All the other data
supporting the finding of this study are available within the article and its supplementary
information files and from the corresponding authors upon reasonable request. A
reporting summary for this article is available as a Supplementary Information file.
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Basilico_NCpaper_Code).
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